Abstract:The overactivation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signal transduction pathway has been examined in various carcinomas and is reported to be significantly correlated with prognosis. However, little is known with regard to the PI3K/Akt signal transduction pathway in advanced non-small cell lung carcinoma (NSCLC). The present study investigated the expression of PI3K and phosphorylated (p)-Akt protein and its clinical significance in NSCLC. The clinical records of 157 patients with NSCLC (70 stage I-IIIA and 87 stage IIIB-IV cases), consisting of 75 cases of squamous cell carcinoma and 82 cases of adenocarcinoma, together with 30 resected lung cancer tumor-adjacent tissue samples, were retrospectively evaluated. PI3K and p-Akt expression in the NSCLC and tumor-adjacent tissues were measured using an immunohistochemical method, and its correlation with the clinicopathological data and prognosis in advanced NSCLC was evaluated. PI3K and p-Akt expression was significantly higher in the cancer tissues (chi(2)=14.8455; P=0.001) than in the tumor-adjacent tissues (chi(2)=14.2615; P=0.001). The overexpression of p-Akt in stage I-IIIA NSCLC was associated with lymph node metastasis (chi(2)=6.1189; P=0.013) and tumor-node-metastasis (TNM) stage (chi(2)=8.9752; P=0.011), however, no correlation was observed with gender, age, pathological type and histological grade. The overexpression of p-Akt in stage IIIB-IV NSCLC was only associated with TNM stage (chi(2)=5.7501; P=0.016), and no correlation was observed with gender, age, Pathological type, histological grade and Eastern Cooperative Oncology Group (ECOG) performance status (PS). The overexpression of PI3K was not found to correlate with the aforementioned clinicopathological variables in all patients. Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 mont hs) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007]. Multivariate analysis showed that PI3K [hazard ratio (HR)=2.143; 95% CI, 1.211-3.790; P=0.009], p-Akt (HR=1.991; 95% CI, 1.009-3.927; P=0.047), TNM stage (HR=4.788; 95% CI, 2.591-8.848; P=0.001) and ECOG-PS (HR=3.272; 95% CI, 1.701-6.296; P=0.001) were independent predictors for survival in stage IIIB-IV NSCLC. These results indicated that p-Akt overexpression closely correlates with factors of an unfavorable prognosis in NSCLC. PI3K and p-Akt overexpression are independent markers of a poor prognosis in advanced NSCLC.

Prognostic significance of signal transducers and activators of transcription 3 and p-signal transducers and activators of transcription 3 expression in patients with non-small cell lung cancer

P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adenocarcinoma

STAT3/p-STAT3 Expression is Correlated with Clinicopathological Characteristics and Prognosis in Non-Small Cell Lung Cancer.

Expression and Prognostic Relevance of Stat3 and Cyclin D1 in Non-Small Cell Lung Cancer

Prognostic Significance of STAT3 Expression and Its Correlation with Chemoresistance of Non-Small Cell Lung Cancer Cells

The Prognostic Value of Expression of Multiple Genes on Resected Non-Small Cell Lung Cancer Tissues

Correlation of pSTAT3 overexpression and prognosis in lung cancer patients: a meta-analysis

Correlation Between Pgsk-3Β Expression and Prognosis in Non-Small Cell Lung Cancer

A Meta-Analysis of STAT3 and Phospho-Stat3 Expression and Survival of Patients with Non-Small-cell Lung Cancer.

The Prognosis of Signal Transducer and Activator of Transcription 3 Expression on Breast Cancer Survival: a Meta-Analysis and Retrospective Study

Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis

Expression and prognostic value of Notch3 and HES1 in non - small cell lung cancer

STAT3, a Poor Survival Predicator, is Associated with Lymph Node Metastasis from Breast Cancer.

Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma.

Expression of STAT3,pSTAT3,VEGF and Bfgf in Tissues of Nonsmall-Cell Lung Cancer

The Role of p-STAT3 as a Prognostic and Clinicopathological Marker in Colorectal Cancer: A Systematic Review and Meta-Analysis

High Expression of the Transcriptional Co-Activator P300 Predicts Poor Survival in Resectable Non-Small Cell Lung Cancers.

Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells.

Expression Profile and Prognostic Values of STAT Family Members in Non-Small Cell Lung Cancer.

The Prognostic Value of Altered Eif3a and Its Association with P27 in Non-Small Cell Lung Cancers.

Multivariate analysis for prognostic predictors in non-small cell lung cancer]